You just read:

Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial

News provided by

Allergan plc

Jun 11, 2018, 08:00 ET